Equitable Access to High-Cost Pharmaceuticals

— —

Zaheer-Ud-Din Babar (Professor in Medicines and Healthcare and Director, Centre of Pharmaceutical Policy and Practice Research, University of Huddersfield, UK)

Equitable Access to High-Cost Pharmaceuticals

Zaheer-Ud-Din Babar (Professor in Medicines and Healthcare and Director, Centre of Pharmaceutical Policy and Practice Research, University of Huddersfield, UK)

$190.95

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Academic Press Inc
21 February 2018

Health economics; Pharmaceutical industries; Public health & preventive medicine

Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.

Edited by: Zaheer-Ud-Din Babar (Professor in Medicines and Healthcare and Director Centre of Pharmaceutical Policy and Practice Research University of Huddersfield UK)
Imprint: Academic Press Inc
Country of Publication: United States
Dimensions: Height: 229mm, Width: 151mm,
Weight: 390g
ISBN: 9780128119457
ISBN 10: 0128119454
Pages: 238
Publication Date: 21 February 2018
Audience: Professional and scholarly , Undergraduate
Format: Paperback
Publisher's Status: Active

1. Access to High Cost Medicines: An Overview 2. Health Technology Assessment 3. High-Cost Medicines in England 4. Managed Entry Agreements and High Cost Medicines (European Perspective) 5. Setting a Public Health Agenda to Support Access to High-Cost Medicines 6. Human Rights and Intellectual Property for Universal Access to New Essential Medicines 7. Access to High Price Medicines in Portugal 8. Improving Access to High-Cost Medicines in Low Income Countries in Africa: Creating a Functioning Pharmaceutical System in Uganda 9. Equitable Access to Biosimilars: An Overview 10. Access to High-Cost Medicines in Europe 11. Access to High-Cost Medicines in Australia 12. Access to High-Cost Medicines in New Zealand 13. Access to High-Cost Medicines in Wales

"Professor Zaheer-Ud-Din Babar is Professor in Medicines and Healthcare and the Director of Centre of Pharmaceutical Policy and Practice Research at the University of Huddersfield, United Kingdom. He is globally known for his work in pharmaceutical policy and practice, including quality use of medicines, clinical pharmacy practice, access to medicines and issues related to pharmacoeconomics. He has published in high impact journals such as PLoS Medicine and the Lancet and has acted as a consultant for World Health Organization, Royal Pharmaceutical Society, Health Action International, International Union Against Tuberculosis and Lung Disease, World Bank, European Union, International Pharmaceutical Federation (FIP) and for the Pharmaceutical Management Agency of New Zealand. His edited work includes ""Economic evaluation of pharmacy services"", “Pharmaceutical prices in the 21st century, “Pharmaceutical policies in countries with developing healthcare systems "", “Global Pharmaceutical Policy, “Pharmacy Practice Research Methods and “Encyclopedia of Pharmacy Practice and Clinical Pharmacy. Published by Elsevier and Adis/Springer, the work is used in curriculum design, policy development and for referral all around the globe. Professor Babar is also the Editor-in-Chief of BMC Journal of Pharmaceutical Policy and Practice and can be contacted at z.babar@hud.ac.uk"

Reviews for Equitable Access to High-Cost Pharmaceuticals

Equitable Access to High-Cost Pharmaceuticals forms an all-inclusive source of knowledge for understanding the issues surrounding access to and cost of new medicines by merging theory with practice, providing a comprehensive outlook on pharmaceutical policy and regulation challenges. --Aris Angelis, The London School of Economics and Political Science